Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07690215

Study to Assess Effectiveness of Oral Atogepant in Adult Participants For Prevention of Migraine in the United Kingdom

Sponsor: AbbVie

View on ClinicalTrials.gov

Summary

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. The study will assess the effectiveness of atogepant for the preventive treatment of migraine in adult patients in the UK. Atogepant is an approved drug for preventive treatment of migraine in adults. Approximately 200 adult participants who are prescribed atogepant by their doctors will be enrolled in this study in the UK. Participants will receive atogepant oral tablets as prescribed by their physician. Participants will be followed for up to week 48. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

Official title: Patient-Reported Outcomes and Healthcare Resource Use in Patients Initiated With Atogepant in a Primary Care Setting for the Prevention of Migraine: An Ambi-spective Real-World Study in the UK (PRACTICE)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

200

Start Date

2026-09-01

Completion Date

2028-03

Last Updated

2026-07-08

Healthy Volunteers

No

Conditions